Kistler-Tiffany Companies’s Acadia Pharmaceuticals ACAD Stock Holding History

Kistler-Tiffany Companies’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-149	Closed	-$7K	–	630
2020 Q2	$7K	Hold	149	–	–	﹤0.01%	477
2020 Q1	$6K	Hold	149	–	–	﹤0.01%	480
2019 Q4	$6K	Hold	149	–	–	﹤0.01%	488
2019 Q3	$5K	Hold	149	–	–	﹤0.01%	504
2019 Q2	$4K	Hold	149	–	–	﹤0.01%	513
2019 Q1	$4K	Hold	149	–	–	﹤0.01%	505
2018 Q4	$2K	Hold	149	–	–	﹤0.01%	525
2018 Q3	$3K	Hold	149	–	–	﹤0.01%	522
2018 Q2	$2K	Hold	149	–	–	﹤0.01%	519
2018 Q1	$3K	Hold	149	–	–	﹤0.01%	511
2017 Q4	$4K	Hold	149	–	–	﹤0.01%	482
2017 Q3	$6K	Hold	149	–	–	﹤0.01%	437
2017 Q2	$4K	Hold	149	–	–	﹤0.01%	443
2017 Q1	$5K	Hold	149	–	–	﹤0.01%	436
2016 Q4	$4K	Hold	149	–	–	﹤0.01%	450
2016 Q3	$5K	Hold	149	–	–	﹤0.01%	468
2016 Q2	$5K	Buy	+149	New	+$4.99K	﹤0.01%	469

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Kistler-Tiffany Companies's ACAD Position: Q3 2020 in Review

Kistler-Tiffany Companies sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 149 shares — an estimated $7K sold.

Kistler-Tiffany Companies first reported a position in ACAD in Q2 2016 and held it in 17 quarters. The position peaked at $7K in Q2 2020. 266 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Kistler-Tiffany Companies reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Kistler-Tiffany Companies sold 149 Acadia Pharmaceuticals shares in Q3 2020, an estimated $7K.
Kistler-Tiffany Companies first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 17 quarters.
Kistler-Tiffany Companies's Acadia Pharmaceuticals position peaked at $7K in Q2 2020.
266 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2020, filed 3 Nov 2020.